Elunetirom Phase 2 Signal Is Real But Registration Case Remains Unbuilt

Autobahn Reports Positive Phase 2 AMPLIFY-BD Results for Elunetirom

Autobahn Therapeutics announced the full results from its Phase 2 AMPLIFY-BD trial for elunetirom, an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist, as an adjunctive treatment for bipolar I or bipolar II depression. The trial demonstrated clinically meaningful benefit and statistical significance across the primary and all key secondary depression endpoints. Patients showed a rapid and robust antidepressant response, with a 16.8-point mean reduction in HAMD-17 at Week 6 (p<0.001), achieving a 75% response rate and 50% remission rate. Significant improvements in functioning were also observed, including an 85% reduction in days lost to depression. These positive results support Autobahn's plans to engage with regulatory agencies for potential registration.

• Elunetirom achieved its primary endpoint, demonstrating a statistically significant 16.8-point mean reduction in HAMD-17 total score at Week 6 (p<0.001), with rapid onset observed by Week 2. Significant improvements were also seen across core depressive symptoms, including depressed mood, work and activities, and psychomotor slowing, as measured by HAMD-6 and HAMD-29 scores, indicating a comprehensive antidepressant effect.
• The trial showed substantial gains in patient functioning, with an 85% reduction in days lost to illness (from 2.7 to 0.4 days per week) and a 62% improvement in Sheehan Disability Scale (SDS) total score at Week 6 (p<0.001). Patient-reported outcomes, including the Symptoms of Depression Questionnaire (SDQ) and Patient Global Impression of Improvement (PGI-I), aligned closely with clinician-rated measures, highlighting meaningful real-world benefits.
• Elunetirom was generally well-tolerated, with no severe or serious treatment-related adverse events reported. Importantly, the trial observed no weight gain, extrapyramidal symptoms, tardive dyskinesia, or clinically meaningful peripheral thyroid effects or ECG findings of concern. The most common treatment-related adverse events were dizziness (14.3%), diarrhea (9.5%), and decreased free thyroxine (9.5%).

Addressing the Persistent Challenges in Bipolar Depression Treatment

Bipolar depression remains one of the most therapeutically complex conditions in psychiatry, complicated by competing risks, tolerability burdens, and gaps in evidence. Current pharmacologic and non-pharmacologic strategies each carry meaningful limitations that affect both acute and long-term outcomes.

• Risk of antidepressant-induced manic switch. Antidepressant use in bipolar disorder carries a treatment-emergent affective switch rate of 24.4% within 8 weeks in one prospective cohort, and as high as 44.3% within 12 weeks in a Nigerian hospital-based review. Clinical risk factors significantly associated with switch include earlier age at onset, higher rate of previous switches, lower rate of prior antidepressant response, female gender, younger age, greater number of previous episodes, and a past history of psychiatric hospitalisation. Notably, a greater number of previous antidepressant exposures was not associated with switch occurrence, and no significant difference in switch rate was observed between adjunct antidepressant therapy with a mood stabiliser or antipsychotic versus combination regimens including all three drug classes.

• Adverse effect burden limiting adherence. The most commonly used pharmacologic therapies — mood stabilisers, atypical antipsychotics, and antidepressants — are associated with frequent side effects including weight gain, metabolic dysregulation, sedation/somnolence, and akathisia. Weight gain and sedation/somnolence in particular negatively affect treatment adherence. Endocrine and metabolic comorbidities, weight gain, and obesity may further reduce the likelihood of positive clinical responses to pharmacologic therapies.

• Differential tolerability across atypical antipsychotics. Atypical antipsychotics approved for bipolar depression vary substantially in their side effect profiles. Lurasidone is associated with higher rates of akathisia, parkinsonism, and hyperprolactinemia relative to other atypical antipsychotics, though it carries relatively lower risk for sedation or overweight/obesity. Lumateperone demonstrated placebo-level rates of weight gain, metabolic shift, prolactin elevation, extrapyramidal side effects, and akathisia in short-term trials of 4–6 weeks, but evidence is largely limited to that timeframe. Quetiapine and olanzapine demonstrated superiority over placebo (p < 0.001) in randomised controlled trials, while both aripiprazole trials failed on the primary efficacy measure after the first 6 weeks.

• Limited options and cognitive concerns in treatment-resistant bipolar depression (TRBPD). Options for TRBPD are limited. Electroconvulsive therapy (ECT) has shown efficacy but is associated with cognitive deficits and memory concerns that lead a significant number of patients to decline continuation. Ketamine infusion and repetitive transcranial magnetic stimulation (rTMS) offer alternatives, though individual responses vary; one case series found that patients who had limited benefit from both ECT and ketamine responded well to deep rTMS, maintaining relative stability for more than 2 years. A single subanesthetic-dose IV ketamine infusion can rapidly improve depressive symptoms within one day, with antidepressant effects lasting three to seven days, but relatively little is known about longer-term effects, including increased risks of abuse and/or dependence.

• Cognitive dysfunction as an undertreated dimension. Patients with bipolar disorder suffer from significant cognitive impairment that contributes directly to functional disability, yet few studies have targeted these symptoms for treatment. A placebo-controlled trial of pramipexole found no compelling cognitive benefit overall; however, strictly euthymic patients fared best (multivariate analysis of variance, P = .03 in euthymic subgroup), and the extent of baseline cognitive impairment also contributed to the likelihood of treatment response, underscoring the importance of rigorous subject selection and study design in this domain.

• Complexity of long-term maintenance management. Because effective acute phase treatments are often continued into maintenance, clinicians must balance efficacy and tolerability for long-term success. The FDA has approved 7 agents for maintenance treatment of bipolar disorder, and given the high risk of recurrent depressive episodes, awareness of which agents more effectively reduce manic or depressive relapses is essential. Ongoing monitoring with rating scales, psychoeducation, and regular assessment of adverse effects are required to optimise adherence and outcomes.

AMPLIFY-BD: Key Efficacy and Safety Outcomes for Elunetirom

Three recent studies illustrate the evolving treatment landscape for bipolar depression across pharmacological and neuromodulatory approaches.

A 2026 retrospective naturalistic study compared high-frequency left-DLPFC repetitive transcranial magnetic stimulation (rTMS) in patients with major depressive disorder and bipolar depressive disorder. Among 161 patients completing 20 sessions of 10 Hz rTMS, the bipolar depression group achieved a response rate of 28.8% versus 48.4% in the MDD group (p = 0.013), while remission rates were comparable between groups (21.2% vs. 21.1%; p = 1.000). Multivariate analysis identified diagnosis (OR = 2.25, p = 0.025), female sex (OR = 2.35, p = 0.014), and lower baseline HAM-D scores (OR = 0.85, p = 0.018) as independent predictors of response. rTMS was well tolerated, with mild transient side effects in 36.6% of participants and only one hypomanic activation reported.

A 2019 study of repeated-dose intravenous ketamine examined six infusions (0.5 mg/kg over 40 minutes) in 97 patients with unipolar (n = 77) and bipolar (n = 20) depression. After the six-infusion course, overall response and remission rates were 68.0% and 50.5%, respectively. Significant decreases in MADRS, suicidal ideation (SSI-part 1), and anxiety (HAMA) scores were observed within four hours of the first infusion and sustained throughout the infusion period. Response at 24 hours after the first infusion was positively associated with final response (OR = 8.94). Dissociative effects, measured by CADSS, showed only a mild and marginally significant increase after the first infusion, with BPRS scores decreasing, supporting an acceptable tolerability profile.

A 2019 systematic review and Bayesian network meta-analysis evaluated lurasidone versus other atypical antipsychotic monotherapies across 14 randomised clinical trials (6,221 patients) in bipolar depression. Lurasidone demonstrated significantly greater MADRS improvement than placebo (−4.70, 95% CrI: −7.20, −2.21), aripiprazole (−3.62, 95% CrI: −7.04, −0.20), and ziprasidone (−3.38, 95% CrI: −6.68, −0.11), with similar results for CGI-BP-S, response, and remission. From a tolerability standpoint, lurasidone was associated with less weight gain than olanzapine (−2.54 kg, 95% CrI: −3.42, −1.67) and quetiapine (−0.83 kg, 95% CrI: −1.59, −0.08), and lower rates of somnolence than quetiapine (OR: 0.33, 95% CrI: 0.11, 0.82) and ziprasidone (OR: 0.34, 95% CrI: 0.09, 0.93), with no significant differences in discontinuation rates or extrapyramidal symptoms across agents.

Elunetirom's Novel Approach Reshapes Bipolar Depression Treatment

The recent announcement from Autobahn Therapeutics regarding the Phase 2 AMPLIFY-BD trial for elunetirom marks a potentially pivotal moment for patients suffering from bipolar I or bipolar II depression. This condition remains a significant challenge for clinicians, with existing treatments often presenting a difficult balance between efficacy and tolerability. For instance, while olanzapine has demonstrated efficacy in bipolar depression, it is associated with notable metabolic side effects, including weight gain and increases in cholesterol and triglycerides. Other agents, like lamotrigine, have shown inconsistent overall efficacy, highlighting the persistent unmet need.

Elunetirom, an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist, offers a novel mechanism of action. The Phase 2 data, showcasing a rapid and robust antidepressant response with a 16.8-point mean reduction in HAMD-17, a 75% response rate, and a 50% remission rate, is compelling. Crucially, the observed 85% reduction in days lost to depression points to a significant improvement in functional outcomes, which is paramount for patients living with this chronic illness.

However, the path forward is not without considerations. The development of thyroid hormone receptor agonists has historically emphasized the importance of receptor selectivity to mitigate potential adverse effects, particularly cardiac issues mediated by THR-α. While elunetirom is described as a CNS thyroid hormone receptor agonist, its specific selectivity profile and potential for systemic effects will be critical to fully understand. Furthermore, while the efficacy data is strong, the comprehensive safety and tolerability profile, especially for long-term use, will be paramount to differentiate it from existing therapies that carry metabolic burdens. The heterogeneity of bipolar depression also suggests that while overall results are positive, future studies will need to confirm consistent efficacy across various patient subgroups. Despite these considerations, the strong Phase 2 results position elunetirom as a promising new therapeutic option, potentially offering a much-needed alternative for patients and a significant strategic asset for Autobahn Therapeutics as they engage with regulatory agencies.